1. Netherlands Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
argenx SE

argenx SE

0QW0.IL
argenx SEGB flagInternational Order Book
865.60
EUR
+11.10
- -
54.15BMarket Cap
argenx SE
0QW0.IL
(International Order Book)

Recent

price

865.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
0.09
0.14
0.24
0.6
0.48
0.82
1.78
0.68
2.03
0.91
9.74
7.55
21.45
36.59
67.76
84.24
Revenue per Share
- -
-0.29
-0.82
-0.54
-1.66
-1.06
-1.19
-1.37
-2.12
-4.69
-13.4
-7.99
-13.05
-5.16
13.92
21.08
27.64
Basic EPS, GAAP
- -
-0.27
-0.71
-0.59
-0.87
-0.99
0.54
-1.8
-1.73
2.72
-8.89
-14.26
-17.78
-8.12
-2.52
9.36
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.65
1.78
1.06
1.91
3.88
2.58
3.31
12.86
17.12
27.6
35.19
49.05
50.79
69.22
90.49
118.34
134.59
Book Value per Share
0.65
1.78
1.06
1.91
3.88
2.58
3.31
12.86
17.12
26.55
31.67
45.73
47.64
67.11
87.5
113.94
130.34
Tangible Book Value per Share
- -
16
16
16
8
16
19
25
36
39
45
51
54
57
60
61
62
Basic Weighted Avg Shares
- -
1
2
4
5
7
15
44
25
78
41
497
411
1,226
2,190
4,153
5,228
Sales/Revenue/Turnover
- -
-323.64
-608.78
-232.69
-286.02
-227.68
-145.56
-62.97
-381.01
-255.04
-1,165.21
-72.37
-176.24
-34.3
-0.81
25.39
30.56
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
1
1
2
4
6
104
111
18
28
- -
Depreciation Expense
- -
-4
-13
-8
-13
-17
-22
-34
-76
-181
-608
-408
-710
-295
833
1,292
1,715
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.78
Effective Tax Rate (%)
- -
-308
-587.4
-229.03
-274.6
-223.4
-145.27
-77.1
-310.22
-230.95
-1,475.29
-82.1
-172.76
-24.06
38.03
31.11
32.81
Profit Margin (%)
10
28
16
29
60
39
73
411
609
1,363
1,729
2,242
2,472
3,701
4,213
5,579
6,493
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
5
6
8
9
15
33
36
36
LT Debt
10
28
17
30
61
41
67
414
616
1,180
1,674
2,534
2,814
4,098
5,498
7,323
8,417
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
21.39
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
23.54
Return on Capital (%)
- -
-23.56
-57.58
-36.32
-27.6
-32.94
-41.86
-14.02
-14.81
-20.18
-42.63
-19.4
-26.54
-8.54
17.36
20.15
23.64
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
11
- -
11
LT Borrowings
- -
- -
- -
LT Finance Leases
36
- -
36
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
62
62
63
Market Capitalization
44,265
38,442
50,868

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
6,899
- -
8,068
Cash, Cash Equivalents & STI
4,440
- -
5,184
Accounts Receivable, Net
1,490
- -
1,832
Inventories
474
- -
371
Total Current Liabilities
1,320
- -
1,575
Payables & Accruals
695
- -
925
ST Debt
11
- -
11
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
94.21%
35.08%
33.19%
Free Cash Flow
-189.63%
-97.19%
-479.69%
Net Income, GAAP
23.92%
-68.95%
55.1%
Sales/Revenue/Turnover
187.2%
291.02%
89.64%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
401
478
573
738
2,190
2025
790
948
1,127
1,288
4,153
2026
1,298
1,515
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.04
- -
1.52
- -
13.92
2025
2.77
- -
- -
- -
21.08
2026
5.9
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Humanigen, Inc. (HGENQ)
Sutro Biopharma, Inc. (STRO)
Cellectis S.A. (CMVLF)
ChitogenX Inc. (CHGX.CN)
Sesen Bio, Inc. (SESN)
Arrowhead Pharmaceuticals, Inc. (0HI3.L)
Business
argenx SE is a biotechnology company that discovers and develops antibody-based therapeutics for cancer and autoimmune diseases, focusing on engineered antibodies and antibody-drug conjugates that modulate immune responses and target disease pathways. Its core products and services span the discovery, development, manufacturing, and commercialization of therapeutic antibodies and related modalities, including antibody formats, bispecific antibodies, and novel immune-oncology programs; collaboration and licensing arrangements with pharmaceutical partners; early and late-stage clinical development, including Phase I-III trials; biomarker and translational science support; GMP-compliant manufacturing and process development for clinical and commercial supply; and regulatory submissions and commercialization activities for approved therapies. Latest major company changes include ongoing strategic collaborations and licensing deals with global biopharma entities to advance pipeline programs; acquisitions or asset acquisitions within the immunology and oncology space to expand therapeutic portfolios; the advancement of key clinical programs through pivotal trial readouts or regulatory submissions; expansion of manufacturing capabilities and capacity through investments in process development and facility upgrades; and corporate governance updates or reorganizations aligned with growth and global commercialization strategies. Additional context: - Industry and segments: biotechnology; immunology, oncology, autoimmunity; research and development, clinical development, regulatory affairs, manufacturing, and commercialization - Target markets: patients with cancer and autoimmune disorders; research and development partners; contract manufacturing and collaboration agreements - Geographic operations: headquarters in Europe with global clinical development activities and regional commercialization; operations and collaborations across North America, Europe, and Asia - Founding year and headquarters: founded in 20XX (specific year not stated here) with headquarters in Europe - Subsidiaries/parent: operates as a standalone publicly traded company with potential subsidiaries or affiliates supporting research, development, manufacturing, and regional commercial activities